Leadership: Page 2
-
Courtesy of BioMarin Pharmaceutical
BioMarin taps Amgen, Roche vets in executive reshuffle
Greg Friberg and James Sabry will take over, respectively, as heads of R&D and business development, less than a year after BioMarin named a new CEO.
By Jacob Bell • Aug. 22, 2024 -
Permission granted by Reed Tuckson
Lessons from COVID: Tuskegee impacts still erode trust in healthcare, but hope shines through
A long-time leader in public health and outreach to people of color, Dr. Reed Tuckson offers the lessons he learned from the COVID pandemic and how pharma can better serve those communities.
By Michael Gibney • Aug. 15, 2024 -
Explore the Trendline➔
Stock via Getty Images
TrendlineCommercialization, marketing and social media
As the pharma industry stares down a historic patent cliff, macroeconomic headwinds and challenging R&D costs for increasingly complex medicines, nailing the launch of new medicines has become increasingly critical.
By PharmaVoice staff -
Getty Images via Getty Images
Q&A // Biotech SpotlightA biotech’s difficult journey to bring a new kind of Parkinson’s drug to patients
A series of executive turnovers at Gain Therapeutics this year precedes important early-stage Parkinson’s results that could change how the disease is treated.
By Michael Gibney • Aug. 13, 2024 -
Spencer Platt via Getty Images
Pharma execs react to final drug price negotiations with Medicare
Here’s what the leaders of the companies with the 10 drugs in the first wave of price negotiations with Medicare said about how the new prices will impact their portfolio.
By Amy Baxter • Aug. 9, 2024 -
Permission granted by University of Pennsylvania
Jim Wilson, prominent gene therapy researcher, to depart UPenn
Wilson, who founded UPenn’s gene therapy program three decades ago, will step down to start two new spinouts, Gemma Bio and Franklin Biolabs.
By Ned Pagliarulo • Aug. 5, 2024 -
Stock via Getty Images
OpinionWhat pharma has learned from AI
As AI tools move from hype to a daily reality at pharma companies, here are the insights users are gaining.
By Meagan Parrish • Aug. 2, 2024 -
Stock via Getty Images
Read to lead: 6 books pharma execs swear by
From an epic, alternative reality fantasy to a ‘biography of cancer,’ these six reads have stuck with pharma execs as they navigate how to lead.
By Alexandra Pecci • Aug. 1, 2024 -
Permission granted by Mubadala Capital
Q&AIn biotech’s new market normal, here’s what’s catching this investor’s eye
A VC investor shares how the market is recovering, which kinds of companies he’s hunting for and where he’d love to see more innovation.
By Meagan Parrish • July 25, 2024 -
Chris duMond via Getty Images
Where Kamala Harris stands on three key pharma issues
The presumptive Democratic nominee has a long history of taking on pharma over drug prices and supporting women’s healthcare access.
By Amy Baxter • July 24, 2024 -
Justin Sullivan via Getty Images
Gilead’s CMO to depart next year
Merdad Parsey joined Gilead as its chief medical officer in 2019 and has helped lead the company’s expansion into oncology, with mixed success.
By Ned Pagliarulo • July 19, 2024 -
Permission granted by Gilead
Gilead eyes ‘ending the HIV epidemic’ via incremental progress
With a long elusive HIV cure ever on the horizon, Gilead’s latest long-acting PrEP study shows that every step counts.
By Michael Gibney • July 18, 2024 -
Permission granted by Amylyx
Q&AAmylyx’s CEOs on their ALS setback and quest to revamp the pipeline
Co-CEOs Josh Cohen and Justin Klee reflect on what they learned from Relyvrio’s failure and how they’re carrying those lessons forward with other drugs.
By Meagan Parrish • July 17, 2024 -
Jeenah Moon via Getty Images
Pfizer research chief Dolsten to step down, with company at a crossroads
The company has begun searching for a successor to Dolsten, who oversaw more than 35 drug and vaccine approvals alongside notable setbacks during his time as Pfizer’s top scientist.
By Ben Fidler • July 10, 2024 -
Permission granted by GeoVax
In the rapidly shrinking COVID market, this company still sees opportunity
GeoVax is developing a next-gen COVID vaccine targeting a population that’s so far been elusive: immunocompromised patients.
By Alexandra Pecci • July 3, 2024 -
Permission granted by BeiGene
Q&AHow BeiGene is taking on established blockbusters with an expanding blood cancer arsenal
BeiGene’s Brukinsa is the first in a hematology franchise that the company hopes will rival top-sellers and introduce a new lineup of medicines for patients.
By Michael Gibney • July 2, 2024 -
Permission granted by Prologue Medicines
Biotech SpotlightProtein power: a biotech mining viruses to fight disease
Flagship Pioneering-backed Prologue Medicine is harnessing the evolutionary tactics of viral proteins to systematically find new drugs.
By Kelly Bilodeau • July 1, 2024 -
Permission granted by Geron
After 33 years, Geron’s first approval marks a turn in Nobel-winning science
The decades-long story of how a first-in-class blood cancer treatment went from bench to bedside.
By Alexandra Pecci • June 26, 2024 -
Christoph Burgstedt via Getty Images
Q&A // First 90 DaysAfter an obesity deal with Novo, Omega’s new business head is on the hunt for more partners
With a career focused on striking deals, Kaan Certel is hoping to lead the Flagship-backed biotech with an mRNA platform into its next phase of growth.
By Amy Baxter • June 24, 2024 -
iStock via Getty Images
Avoiding the pharma ‘junk pile’ with launch readiness, pipeline rigor and ‘quick kills’
Drug launches have underperformed expectations at a high rate, and pharmas need to get better at thinning the pipeline to make room for the real wins, says a life sciences consultant.
By Michael Gibney • June 18, 2024 -
Igor Kutyaev via Getty Images
Making MovesRegenxbio CEO to step down after 15 years
Kenneth Mills will become chair of the gene therapy developer's board while Curran Simpson, the current chief operating officer, will take his place as company head.
By Ned Pagliarulo • June 13, 2024 -
Christopher Furlong via Getty Images
As Big Pharma places bigger bets on ADCs, here’s where the field is headed next
With more drugmakers getting into the antibody-drug conjugate game, emerging innovations signal a bright future for the technology.
By Michael Gibney • June 11, 2024 -
Permission granted by Bristol-Myers Squibb
Behind Big Pharma’s layoffs — is there an end in sight?
A slew of major companies, including BMS, have announced cost-cutting measures in recent months. What will it take to turn the tide?
By Kelly Bilodeau • June 10, 2024 -
Stock via Getty Images
Pharma’s R&D gamble: picking pipeline winners in a risky field
How leaders from biotech, Big Pharma and the investment world know when they've found the right candidate or company to back.
By Meagan Parrish • June 7, 2024 -
Permission granted by City of Hope
A ‘widening gap’ in access to new cancer meds drives efforts from City of Hope and Bristol Myers
Cancer care is improving so quickly that receiving newer medications can be difficult — City of Hope’s wide oncology network and a 10-year commitment from Bristol Myers Squibb offer some solutions.
By Michael Gibney • June 6, 2024 -
Courtesy of Merck & Co.
Merck and Moderna’s cancer vaccine snags a clinical win in a field decades old
Cancer vaccines are taking off in the clinic, and a partnership between Merck and Moderna is at the forefront of a new wave of immunotherapy.
By Michael Gibney • June 3, 2024
Previous
